A recent study conducted by researchers at the Christie NHS Foundation Trust in Manchester suggests that the timing of cancer immunotherapy treatments may influence patient survival rates. The study analyzed outcomes for 2,631 patients with various cancer types—including lung cancer, melanoma, kidney cancer, and head and neck cancer—who received immunotherapy at the Christie between 2018 and 2023.

According to the findings, patients who received the majority of their immunotherapy sessions in the morning had a median overall survival of 21.4 months, compared with 13.1 months for those treated predominantly later in the day. Immunotherapy was administered as an infusion approximately every two to six weeks, and treatments on average took place around 12:49 pm.

The researchers propose that circadian rhythms— the body’s natural 24-hour biological clock—may play a role in how the immune system responds to cancer treatment. Immune cells are thought to be more active in the early part of the day, potentially enhancing the body’s ability to attack cancer cells following immunotherapy. This concept aligns with existing evidence that immune responses to interventions such as vaccination and cancer therapy can vary depending on the time of day.

While the study’s results indicate a notable association between treatment timing and survival, the authors emphasize that the data are observational and do not establish a direct causal relationship. Paul Lorigan, a consultant medical oncologist at the Christie and senior author of the study, remarked that timing alone cannot be conclusively identified as the responsible factor for improved outcomes.

The researchers suggest that optimizing treatment schedules to favor morning administration could be a relatively simple strategy to improve patient outcomes without introducing new drugs or additional side effects. However, further research is needed to determine whether changes in clinical practice based on these findings would yield consistent benefits across broader patient populations.

The findings were published in the British Journal of Cancer and contribute to a growing body of literature exploring the interaction between circadian biology and therapeutic efficacy in oncology.